Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: Implications for molecular targeted therapy

Annals of the Rheumatic Diseases

Volumn 73, Issue 5, 2014, Pages 945-947

  Nishina, Naoshi ^a   Kikuchi, Jun ^a   Hashizume, Misato ^b   Yoshimoto, Keiko ^a   Kameda, Hideto ^a,c   Takeuchi, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c Institute for Advanced Medical Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB;

ADULT; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LETTER; MALE; MOLECULARLY TARGETED THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

CYTOKINES; DISEASE ACTIVITY; DMARDS (BIOLOGIC); RHEUMATOID ARTHRITIS; TREATMENT;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERLEUKIN-6; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RECEPTORS, INTERLEUKIN-6; REMISSION INDUCTION;

EID: 84898003691     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204137     Document Type: Letter

References (7)

1. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22:347-52.
2. Mihara M, Hashizume M, Yoshida H, et al. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012;122:143-59.
3. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61. (Pubitemid 30017224)
4. Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:1208-15.
5. Todd DJ, Knowlton N, Amato M, et al. Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor. Arthritis Rheum 2011;63:894-903.
6. Uson J, Balsa A, Pascual-Salcedo D, et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997;24:2069-75. (Pubitemid 27474022)
7. Rodriguez-Rodriguez L, Lamas JR, Varade J, et al. Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL6R polymorphism and with disease activity. Rheumatol Int 2011;31:409-13.